Analytical methods for sugar chains

By employing a process of ionization, recovery, hydrophobication, and detection, combined with supercritical liquid chromatography and tandem mass spectrometry, the problem of insufficient sensitivity in glycan analysis in existing technologies has been solved. This enables simple and highly sensitive glycan analysis, particularly for the detection of atomolar levels in antibody samples, shortening the determination time and improving analytical efficiency.

CN117545851BActive Publication Date: 2026-11-10JAPANESE FOUND FOR CANCER RES +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202280042665.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-08-27
Filing Date
2022-06-28
Publication Date
2026-11-10
Estimated Expiration
2042-06-28

AI Technical Summary

Technical Problem

Existing glycan analysis methods are insufficient in sensitivity and cannot effectively detect glycans at the sub-picomolar level. Furthermore, capillary electrophoresis requires complex electrophoretic conditions, making it difficult to achieve highly sensitive glycan analysis.

Method used

The method employs a process involving ionization, recovery, hydrophobication, and assay. By adding a sugar-cleaving enzyme, the sugar chains bonded to the antibody are released. After recovery via affinity purification, the antibody is hydrophobized and then detected by supercritical liquid chromatography and tandem mass spectrometry.

Benefits of technology

This invention enables a simple and highly sensitive glycan analysis method that can detect antibody samples at atomolar levels, shortens the assay time, provides a high-throughput glycan analysis method, and reliably analyzes the inhomogeneity of glycan structures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117545851B_ABST
    Figure CN117545851B_ABST
Patent Text Reader

Abstract

The analytical method for glycans is a method for analyzing the glycan structure bonded to antibodies. It includes: a cleavage step, in which a glycolytic enzyme is added to the antibody-containing sample to specifically cleave the glycans bonded to the antibody, resulting in free glycans; a recovery step, in which the free glycans are recovered through affinity purification; a hydrophobication step, in which the free glycans are hydrophobized to obtain hydrophobic glycans; and a determination step, in which the hydrophobic glycans are sequentially analyzed by supercritical liquid chromatography and tandem mass spectrometry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to a method for analyzing the glycan chains bonded to antibodies. Background Technology

[0002] Antibodies are composed of heterogeneously bonded glycan chains with diverse structures, and the types and proportions of these glycan chains can affect the antibody's function and efficacy. Therefore, analyzing the glycan chains bonded to antibodies is crucial.

[0003] Conventional analytical methods for this purpose involve fluorescently labeling the glycans cleaved from antibodies and analyzing them using high-performance chromatography (fluorescent HPLC) (Non-Patent Literature 1). In recent years, glycan analysis methods using matrix-assisted laser desorption / ionization mass spectrometry (MADS) and gas chromatography-mass spectrometry (GC-MS) have been reported (Non-Patent Literature 2). Furthermore, capillary electrophoresis-mass spectrometry (CES-MS) has been reported as a highly sensitive analytical method (Non-Patent Literature 3).

[0004] Existing technical documents

[0005] Non-patent literature

[0006] Non-patent literature 1: mAbs 7:1,167-179; January / February 2015; Published with license by Taylor & Francis Group, LLC

[0007] Non-patent literature 2: Nature Protocols, 2007, Vol.2, No.7, pp.1585-1602.

[0008] Non-patent literature 3: Nature Communications 2019 10:2137. Summary of the Invention

[0009] The problem the invention aims to solve

[0010] However, the analytical methods in Non-Patent Literature 1 and 2 can only detect glycan concentrations at the sub-picomolar level (e.g., 0.03 picomolars), which is insufficiently sensitive. On the other hand, while the analysis in Non-Patent Literature 3 can detect glycans at the attomolar level, the capillary electrophoresis conditions are cumbersome and difficult to set. Therefore, alternative methods are needed as highly sensitive glycan analysis methods.

[0011] The purpose of this invention is to provide a simple and highly sensitive method for analyzing the glycan chains of antibodies.

[0012] Solution for solving the problem

[0013] The analytical method of the first aspect of the present invention is a method for analyzing the structure of glycans bonded to an antibody, comprising: a cleavage step, wherein a glycolytic enzyme is added to a sample containing an antibody to specifically cleave the glycans bonded to the antibody to obtain free glycans; a recovery step, wherein the free glycans are recovered by affinity purification; a hydrophobication step, wherein the free glycans are hydrophobized to obtain hydrophobic glycans; and a determination step, wherein the hydrophobic glycans are sequentially analyzed by supercritical liquid chromatography and tandem mass spectrometry.

[0014] The effects of the invention

[0015] The analytical method described in the first approach allows for simple and highly sensitive analysis of the antibody's glycan chains. Attached Figure Description

[0016] Figure 1 A block diagram of the analysis method of the first approach is shown.

[0017] Figure 2 The analytical apparatus used in the analytical method of the first method is shown.

[0018] Figure 3 The structural formulas and schematic diagrams of the sugar chains and their acetylated sugar chains, which are the subjects of analysis, are shown.

[0019] Figure 4 The MRM spectrum of the antibody (bevacizumab) measured in Example 1 is shown.

[0020] Figure 5 The spectrum of the antibody (bevacizumab) measured in Example 1 is shown (the amount of antibody is 10 amol).

[0021] Figure 6 A graph showing the relationship between the types of glycan structures and their relative amounts across batches of the antibody (bevacizumab). Detailed Implementation

[0022] 1. Method 1

[0023] like Figure 1 As shown, the analytical method of the first aspect of the present invention sequentially performs a freeing step, a recovery step, a hydrophobication step, and a measurement step. Each step is described in detail below.

[0024] (Free process)

[0025] In this process, a sugar-cleaving enzyme is added to the sample to specifically release the sugar chains bonded to the antibody.

[0026] First, prepare a sample containing antibodies. The antibody can be either a monoclonal antibody or a polyclonal antibody. Examples of monoclonal antibodies include: ramucirumab, nivolumab, panitumumab, offatumumab, golimumab, ipilimumab, and adalimumab; and trastuzumab, bevacizumab, tocilizumab, trastuzumab-DM1, omalizumab, mepolizumab, and gemulizumab. Humanized antibodies such as uzumab, palivizumab, ranibizumab, certolizumab, ozolizumab, mogamulizumab, eculizumab, tildrakizumab, and mepolizumab; chimeric antibodies such as rituximab, cetuximab, infliximab, and basiliximab; mouse antibodies, etc.

[0027] Antibodies are typically prepared in the following forms: intravenous injections, subcutaneous injections, and other formulations; and in biological samples such as blood, serum, plasma, saliva, nasal mucus, intestinal secretions, tissues, and cells. These formulations and biological samples may undergo pretreatment such as removal of impurities as needed.

[0028] Antibodies have N-bonded glycans (N-type glycans), O-bonded glycans (O-type glycans), and other glycans bonded to them. A desired antibody region containing the bonded glycans is selected, and the glycans are released from that antibody region using known methods.

[0029] As the sugar-cleaving enzyme, any known enzyme can be used as long as it can cleave the sugar chain from the antibody. Examples include N-glycosidase, O-glycosidase, endoglycoceramidase, and the like. Specifically, when releasing the N-linked sugar chain bonded to the 297th asparagine (Asn-297) in the Fc region of an antibody, enzymes such as peptide-N-glycosidase F (PNGase F), peptide-N-glycosidase A (PNGase A), endo-β-N-acetylglucosaminidase (Endo M) can be used. The addition amount and reaction conditions may follow the protocol accompanying the catalyst used, for example, heat-based denaturation and incubation are appropriately performed in a buffer solution containing the antibody and the sugar-cleaving enzyme.

[0030] Free sugar chains are thus obtained. It is preferable to obtain the N-linked sugar chain bonded to the 297th asparagine in the Fc region of the antibody. At this time, the free sugar chains are obtained in the state of a digestion mixture that simultaneously contains the antibody (after sugar chain cleavage), the sugar-cleaving enzyme, and impurities.

[0031] (Recovery step)

[0032] In this step, free sugar chains are recovered by affinity purification. That is, the free sugar chains are separated or fractionated.

[0033] In affinity purification, the sugar chains are adsorbed onto a carrier, the carrier with the adsorbed sugar chains is washed, and then the sugar chains are eluted into a desired solvent. Since sugar chains are generally hydrophilic and antibodies are hydrophobic, carriers with hydrophilic surfaces can be used. Examples of such carriers include hydrophilic beads such as cross-linked agarose gel beads, carboxyl beads, dextran beads, and silica beads. Specific examples include cross-linked agarose gel CL-4B beads (manufactured by SIGMA-Aldrich), Dynabeads M-270, M280 (manufactured by Thermo Fisher), and the like. Examples of the solvent for eluting sugar chains include aqueous solvents such as water. After purification, the free sugar chains are dried as needed. It should be noted that the affinity purification in the present invention also includes solid phase extraction using a graphitized carbon column or the like.

[0034] Free sugar chains can thus be recovered. It is preferable to isolate the N-linked sugar chain bonded to the 297th asparagine in the Fc region of the antibody. At this time, the isolated free sugar chains may be the free sugar chains themselves, or may be in a state contained in an organic solvent.

[0035] (Hydrophobization step)

[0036] In this step, the free sugar chains are hydrophobized. For example, the hydroxyl groups possessed by the free sugar chains are modified (protected) with a hydrophobic compound.

[0037] Examples of hydrophobication methods include acylation such as acetylation, propionylation, butyrylation, and benzoylation; alkoxymethylation such as methoxymethylation; silylation such as trimethylsilylation, triethylsilylation, and tert-butyldimethylsilylation; and triphenylmethylation. From the viewpoint of better retention of the stationary phase in supercritical fluid chromatography, acylation is preferred, and acetylation is more preferred.

[0038] Hydrophobic compounds are compounds that react with the hydroxyl groups of sugar chains to make those hydroxyl groups hydrophobic. They can be selected from known acylating agents, alkoxymethylating agents, silylating agents, triphenylmethylating agents, etc.

[0039] When performing acetylation, acetylation agents that are hydrophobic compounds can include, for example, acetic anhydride, acetyl chloride, acetylimidazolium, N-acetylsuccinimide, acetylimine acetate, and acetylimidazolium. Catalysts such as pyridine, triethylamine, sodium acetate, sodium carbonate, sodium bicarbonate, potassium carbonate, imidazole, sodium hydride, sodium methoxide, and sulfuric acid can be added as needed during acetylation. The acetylation reaction can be carried out, for example, at 20–80°C for 1–10 hours.

[0040] This yields hydrophobic sugar chains. Preferably, acetylated sugar chains are obtained. Through hydrophobization, the sugar chains can be readily dissolved in the supercritical fluid and easily retained in the stationary phase in the SFC described later. That is, SFC determination becomes possible.

[0041] (Measurement Procedure)

[0042] In this process, hydrophobic sugar chains are used as the test samples, and supercritical fluid chromatography (SFC) and tandem mass spectrometry (MS / MS) are performed sequentially.

[0043] First, SFC is performed on the hydrophobic sugar chains. SFC is a chromatographic technique that uses a supercritical fluid as the mobile phase to separate the sample. (See reference...) Figure 2 The device 1 used in SFC includes at least a mobile phase container 2, a pump 3, a sample inlet 4, a column 5, a detection unit 6, and a computer 7. It may also include a modifier container 8, a makeup solvent container 9, and pumps 10 and 11 for transporting these components, as needed.

[0044] Regarding fluids used as mobile phases, examples include CO2, NH2, N2O, H2O, C3H8, and C6H4O. 14 Examples include CH3OH, C2H5OH, and C6H5CH3. From the perspective of easily entering a supercritical state and inhibiting its effects on the human body, CO2 is the preferred choice.

[0045] The stationary phase only needs to be able to retain or separate hydrophobic sugar chains, and examples include supports having hydrophobic groups. Examples of hydrophobic groups include phenyl (-C6H5), octadecyl, carbamoyl, aminopropyl, cholesterol, pentabromobenzyl, pyrene ethyl, pyridyl, triazolyl, 3-chloro-4-methylphenyl, etc. Among these, substituted or unsubstituted phenyl groups are preferred, and unsubstituted phenyl (-C6H5) groups are particularly preferred. This results in excellent interaction with hydrophobic sugar chains, especially acetylated sugar chains, thus enabling the retention and separation of hydrophobic sugar chains. Furthermore, the separation time can be short, around 3 to 7 minutes, thus significantly reducing the time required for high-throughput screening.

[0046] Examples of carriers that can be modified with hydrophobic groups include silica beads, acrylic beads, and agarose beads.

[0047] Examples of columns with such a fixed phase include the Shim-pack US series (registered trademark) manufactured by Shimadzu Corporation, the CHIRAL PAK series (registered trademark) manufactured by Celestron Corporation, and the Cellulose-C series manufactured by YMC Corporation.

[0048] Modifiers only need to adjust the solubility of hydrophobic sugar chains in fluids. Examples of such modifiers include organic solvents such as methanol, ethanol, 2-propanol, hexane, acetone, isooctane, acetonitrile, tetrahydrofuran, ethyl acetate, dichloromethane, chloroform, 1,4-dioxane, diethyl ether, diisopropyl ether, dimethylformamide, and dimethyl sulfoxide.

[0049] As modifiers, acids such as formic acid and acetic acid can be added; salts such as ammonium formate and ammonium acetate; bases such as diethylamine and ammonia. From the viewpoint that hydrophobic sugar chains dissolve well in fluids, carboxylic acids or their salts are preferred.

[0050] In SFC determination, free sugar chains (sample 12) are first introduced into the sample inlet (autosampler) 4. The free sugar chains 12 are mixed and dissolved with supercritical fluid and modifier pumped from the mobile phase container 2 and modifier container 8 by pumps 2 and 10, and then conveyed to the column 5. In the column 5, the free sugar chains are separated and discharged according to the elution time through interaction with the stationary phase. The separated free sugar chains are detected in the detection unit 6 and processed into data such as spectra by the computer 7. The free sugar chains are then subjected to tandem mass spectrometry analysis.

[0051] Preferably, a replenishing solvent is added to the free sugar chains (specifically, the fluid containing free sugar chains) after passing through the stationary phase of column 5. That is, the replenishing solvent is delivered from container 9 via pump 11, and the free sugar chains and replenishing solvent are mixed downstream of column 5. This improves sensitivity in subsequent tandem mass spectrometry analysis. Examples of replenishing solvents include organic solvents containing carboxylic acids or their salts, preferably salts containing carboxylic acids. Examples of carboxylic acids include formic acid and acetic acid; examples of carboxylic acids include ammonium formate and ammonium acetate. Organic solvents listed in the modifier examples are also acceptable.

[0052] Next, tandem mass spectrometry analysis is performed on the free sugar chains supplied to the SFC. Tandem mass spectrometry involves performing at least two mass spectrometry analyses in tandem; it is an analytical method that fragments the ions selected by the first mass spectrometry analysis and detects these fragment ions by the second mass spectrometry analysis. The apparatus used in tandem mass spectrometry analysis has at least two mass spectrometers and a fragment generation unit disposed therebetween. More specifically, such as... Figure 2 As shown, the tandem mass spectrometry analysis device 20 is located downstream of the SFC device 1 and includes an ionization unit 21, a first mass spectrometer 22, a fragment generation unit 23, a second mass spectrometer 24, a detection unit 25, and a computer 26. The ionization unit 21 is configured to directly input free sugar chains discharged from the SFC device 1. Furthermore, the computer 26 is connected to the computer 7 of the SFC device 1, sharing the spectral results obtained from the SFC device 1, and can compare and analyze them with the results from the detection unit 25.

[0053] Examples of first or second mass spectrometry methods used in tandem mass spectrometry analysis include quadrupole mass spectrometers, sector magnetic field mass spectrometers, time-of-flight mass spectrometers, ion trap mass spectrometers, and ion cyclotron resonance mass spectrometers. Hybrid mass spectrometry analysis using two different mass spectrometers is also included in the tandem mass spectrometry analysis of this invention.

[0054] Examples of methods implemented in the ionization section include electron ionization (EI), electrospray ionization (ESI), and atmospheric pressure chemical ionization (APCI).

[0055] Examples of methods implemented in the fragment generation section include collision-induced dissociation (CID), electron transfer dissociation, electron capture dissociation, infrared multiphoton dissociation, ultraviolet photodissociation, and surface-induced dissociation.

[0056] Specifically, tandem mass spectrometry analysis devices include triple quadrupole mass spectrometers, quadrupole time-of-flight mass spectrometers (Q-TOF MS), quadrupole ion trap mass spectrometers (Q-IT MS), and tandem time-of-flight mass spectrometers. From the viewpoint of high selectivity for the glycans to be analyzed, ease of operation, and the ability to perform measurements with higher sensitivity, triple quadrupole mass spectrometers are preferred.

[0057] In tandem mass spectrometry analysis, the free sugar chains delivered by the SFC device 1 are ionized in the ionization section 21. Using the first mass spectrometer 22, only the ionized free sugar chains with a specific m / z (precursor ions) are introduced into the fragmentation section 23. In the fragmentation section 23, the specific ionized free sugar chains are decomposed into secondary ions (product ions) through dissociation methods such as collisions with an inert gas. The product ions are then passed through the second mass spectrometer 24, where only product ions with a target m / z (a value smaller than the m / z of the precursor ions) are introduced into the detection section 25 for detection, and analysis is performed by the computer 26.

[0058] At this time, the information of all types of precursor ions to be detected (structure of hydrophobic glycans, m / z, etc.) is pre-input into the first mass spectrometer (Q1 precursor ion-daughter ion pair (Q1 transition)). Specifically, Table 1 as described in the examples can be listed. The range of m / z of the precursor ions to be introduced into the fragment generation section can be set to 500 or more, preferably 700 or more, and can also be set to 2000 or less, preferably 1500 or less. It should be noted that when using glycans obtained by enzyme cleavage at Asn-297, the glycans contain a large number of Figure 3 The glycan chain shown in (a). Therefore, it is preferable to select and detect at least the m / z value of the precursor ion formed by acetylation of the glycan (specifically m / z = 1173). That is, the precursor ion with m / z of 1173 is preferably selected in the first mass spectrometer. This allows for the detection of the glycan as a major component. Figure 3 The sugar chain of (a).

[0059] In the second mass spectrometer (Q3 precursor ion-daughter ion pair), from the viewpoint of detecting fragments of the glycan structure, the m / z range of the product ion introduced into the detection unit can be set to, for example, less than 500, preferably less than 250, and can also be set to, for example, more than 100, preferably more than 200. Particularly preferred are product ions selected at least when acetylated free glycans undergo fragmentation (e.g., [HexNc+Ac-2H2O)). + The m / z value (specifically m / z = 210) of the oxonium ion of acetylated and dehydrated N-acetylhexosamine. That is, it is preferred to detect the product ion with m / z of 210.

[0060] Therefore, the desired glycan structure can be detected. Specifically, refer to... Figure 4 (As will be described in Example 1 below), as mass spectrometry analysis data, multiple reaction monitoring (MRM) spectra that can be decomposed into each desired glycan structure are obtained. That is, spectra of glycan structures corresponding to the m / z settings in the first and second mass spectrometers are obtained.

[0061] At this point, the structure of the glycans bonded to the antibody is analyzed based on mass spectrometry data obtained through SFC and MS / MS (analysis step). Specifically, based on the m / z detected in the obtained MRM spectrum and the above input information, the type, structure, and content of the glycans bonded to the antibody are determined. This can be performed using known or commercially available software.

[0062] The desired sugar chain can be detected from this spectrum. Furthermore, for each sugar chain, a standard curve showing the relationship between the peak intensity of the spectrum measured at a known content (or concentration) and that content can be prepared in advance. By comparing the sample with this standard curve, the content of the desired sugar chain can also be determined. Alternatively, a standard substance with a known content (or concentration) can be added to the test sample in advance, and the content of the desired sugar chain can be calculated based on the relative ratio of the peak intensity of the standard substance to the peak intensity of the desired sugar chain.

[0063] It should be noted that corrections can be performed in the content calculation as needed. Corrections can be made using well-known methods, or alternatively, appropriate settings can be made. For example, in a first-generation mass spectrometer, precursor ions with an m / z difference of less than 1 (e.g., glycan ions with m / z = 1173.3, A, and glycan ions with m / z = 1173.8) may sometimes be detected simultaneously. In this case, the content can be corrected by adjusting the peak intensities of the ions based on the intensity ratio of the ions obtained using conventional methods such as fluorescence HPLC.

[0064] 2. Method

[0065] Those skilled in the art will understand that the above exemplary embodiments are specific examples of the following methods.

[0066] (Item 1) The analytical method for glycans involved in the method can be: a method for analyzing the glycan structure bonded to an antibody, comprising: a cleavage step, in which a glycolytic enzyme is added to a sample containing an antibody to specifically cleave the glycans bonded to the antibody, thereby obtaining free glycans; a recovery step, in which the free glycans are recovered by affinity purification; a hydrophobication step, in which the free glycans are hydrophobized to obtain hydrophobic glycans; and a determination step, in which the hydrophobic glycans are sequentially analyzed by supercritical liquid chromatography and tandem mass spectrometry. This provides a simple and highly sensitive method for analyzing the glycans of an antibody. In particular, the bonded glycans can be detected even for antibody samples at the attomolar level. This allows for more reliable analysis of the inhomogeneity of the glycan structure. Furthermore, by using SFC as the chromatogram, the elution time can be less than 10 minutes. This significantly reduces the determination time compared to capillary electrophoresis (which requires more than 30 minutes of measurement time). Furthermore, since the glycans expelled from chromatography can be directly transported to the ionization section of tandem mass spectrometry, the measurement is simple and can be performed continuously and smoothly. This enables high-speed glycan analysis and provides a high-throughput glycan analysis method.

[0067] (Item 2) In the analytical method described in Item 1, the above-mentioned determination step may include an analytical step, which analyzes the structure of the glycans bonded to the antibody based on mass spectrometry analysis data obtained by supercritical liquid chromatography and tandem mass spectrometry. This allows for the identification of the type and structure of the glycans.

[0068] (Item 3) In the analytical method described in Item 1 or Item 2, the stationary phase used in the supercritical fluid chromatography described above may contain phenyl groups. Therefore, in supercritical fluid chromatography, free sugar chains can be reliably retained in the stationary phase, and free sugar chains can be separated.

[0069] (Item 4) In the analytical method of any one of items 1 to 3, in the above-described hydrophobication step, the hydroxyl groups of the free sugar chain can be modified with a hydrophobic compound. This allows the free sugar chain to be readily soluble in the supercritical fluid chromatography fluid and reliably retained in the stationary phase.

[0070] (Item 5) In the analytical method described in any one of items 1 to 4, the hydrophobication described above can be acetylation. This allows for the easy hydrophobication (acetylation) of free sugar chains. Furthermore, it exhibits excellent interaction with the stationary phase, particularly a stationary phase containing phenyl groups, and can be reliably retained on the stationary phase.

[0071] (Item 6) In the analytical method described in any one of items 1 to 5, during the above-described determination step, an organic solvent containing a carboxylic acid or its salt may be added to the free sugar chain after passing through the stationary phase of the above-described supercritical liquid chromatography, followed by the above-described tandem mass spectrometry analysis. This further improves the analytical sensitivity of the sugar chain.

[0072] (Item 7) In any of the analytical methods described in items 1 to 6, a triple quadrupole mass spectrometer can be used in the tandem mass spectrometry analysis described above. This allows for more reliable selection of the desired sugar chain and high-sensitivity analysis.

[0073] Example

[0074] The present invention will now be described in detail with examples, but the scope of the invention is not limited by these examples.

[0075] <Example 1>

[0076] (Free process)

[0077] 10 μg of bevacizumab (Avastin: registered trademark, anti-VEGF humanized monoclonal antibody, manufactured by Chugai Pharmaceutical Co., Ltd.) as the antibody was mixed with Rapid PNGase F reagent (manufactured by New England Biolabs) according to the manufacturer's instructions. This yielded a digestion mixture that released the N-type glycan chain from the antibody's Asn-297.

[0078] (Recycling process)

[0079] The digestion mixture was adjusted to 85% (v / v) acetonitrile and dispensed onto a filter plate along with 50 μL of cross-linked agarose CL-4B beads (50% slurry, manufactured by SIGMA-Aldrich). It was then adjusted with 200 μL of water and equilibrated with 85% (v / v) acetonitrile. This allowed free sugar chains to adsorb onto the beads. The sugar-adsorbed beads were washed twice with a solution containing 85% (v / v) acetonitrile and 0.1% (v / v) trifluoroacetic acid, followed by two washes with 85% (v / v) acetonitrile. The free sugar chains were then eluted into 100 μL of water and vacuum dried.

[0080] (Hydrophobication process)

[0081] The free sugar chain was mixed and reacted with 5 μL of acetic anhydride and 5 μL of dehydrated pyridine at 50 °C for 4 hours. After acetylation, the mixture was dried using a centrifugal concentrator. This yielded the acetylated sugar chain.

[0082] (Measurement Procedure)

[0083] Acetylated sugar chains were prepared in amounts equivalent to 5000 fmol, 500 fmol, 50 fmol, 5 fmol, 500 amol, 50 amol, 10 amol, and 5 amol of antibody. Specifically, all acetylated sugar chains obtained from 10 μg of antibody were dissolved in methanol, appropriately diluted and separated, and adjusted to 2 × 10⁻⁶ relative to the total amount. 6 One-third, 2×10 7 One-third, 2×10 8 One-third, 2×10 9 One-third, 2×10 10 One-third, 2×10 11 One-third, 1×10 12 One-third and 2×10 12 One-tenth of the amount. Use these as the test sample.

[0084] For each sample to be measured, a supercritical fluid chromatography system (NexeraUC, manufactured by Shimadzu Corporation) and a triple quadrupole mass spectrometer (LCMS-8050, manufactured by Shimadzu Corporation) were combined and continuously measured (see reference). Figure 2 The conditions are as follows.

[0085] (1) Supercritical fluid chromatography

[0086] Mobile phase: CO2 (99.99% purity, manufactured by Iwatani Corporation)

[0087] Modifier: Methanol (LC / MS level)

[0088] Injection volume: 2.5 μL

[0089] Flow rate: 1.0 mL / min

[0090] Column temperature: 40℃

[0091] Column: Shim-pack UC-Phenyl (containing -C6H5 group, 2.1×150mm, particle size 3μm: manufactured by Shimadzu Corporation)

[0092] Gradient conditions: 10% methanol (0 minutes) - 40% methanol (4 minutes) - 40% methanol (7 minutes) - 10% methanol (7.1 minutes) - stop (8.5 minutes).

[0093] Supplemental solvent: Methanol containing 0.1% (v / v) ammonium formate

[0094] Replenishment solvent flow rate: 0.1 mL / min

[0095] (2) Triple quadrupole mass spectrometry analysis

[0096] Interface voltage: 4000V

[0097] Interface temperature: 225℃

[0098] Heating block temperature: 400℃

[0099] Desolventizing temperature: 225℃

[0100] CID gas pressure: 270 kPa (argon)

[0101] In the Q1 precursor ion-daughter ion pair, the m / z of the precursor ion is input and set in a manner that covers all envisioned glycan compositions, as shown in Tables 1 and 2 below. In the Q3 precursor ion-daughter ion pair, the m / z of the product ion is set to 210, and the dehydrated fragment ion of the acetylated glycan chain (GlcNAc) (i.e., [HexNAc+Ac-2H2O)) is... + The ion was set as the reporter ion. A scan was performed using the collision energy (CE) at m / z = 210, and the setting was configured to maximize the intensity of the acetylated sugar chain fragment ion. The acquired data was processed using LabSolutionsLCMS software (manufactured by Shimadzu Corporation) (analysis step).

[0102] [Table 1]

[0103]

[0104] [Table 2]

[0105]

[0106] Figure 4 The results are shown when the antibody is equivalent to 500 fmol. Figure 5 The results are shown when the antibody is equivalent to 10 amol (only the peak of glycan ID43100 is extracted). Table 3 shows the results indicating the relationship between the amount of antibody and the peak intensity area of ​​the strongest peak in the spectrum.

[0107] [Table 3]

[0108] antibody levels Peak area Coefficient of variation (cv)% 5amol 174.2 24.0 10amol 276.2 10.9 50amol 1225.4 9.0 500amol 10933 8.4 5fmol 122223 5.0 50 fmmol 1037569 3.4 500 fmmol 6205217 3.9 5000 fmol 25954461 2.3

[0109] As can be seen from this, even at atomolar levels such as 5 amol of antibody, the assay method of this embodiment can accurately detect the bonded glycan chains (limit of detection). Therefore, the sensitivity is exceptionally superior compared to the limit of detection of 0.03 pmol for conventional fluorescent HPLC methods.

[0110] <Examples 2-5: Analysis of various antibodies>

[0111] The following antibody was used instead of bevacizumab as the antibody, and the procedure was otherwise performed in the same manner as in Example 1 above, measuring the glycan chains of the antibody. The results showed that, similar to bevacizumab, the bound glycan chains could be detected at an antibody concentration of 5 amol.

[0112] Example 2: Ramucirumab (Cyramza: registered trademark, manufactured by Eli Lilly Japan)

[0113] Example 3: Trastuzumab (Herceptin: registered trademark, manufactured by Chugai Pharmaceutical Co., Ltd.)

[0114] Example 4: Nivolumab (Opdivo: registered trademark, manufactured by Ono Pharmaceutical Co., Ltd.)

[0115] Example 5: Rituximab (Rituxan: registered trademark, manufactured by Rituxan Pharmaceuticals Inc.)

[0116] <Example 6: Confirmation of Glycan Structure Inhomogeneity Between Antibody Batches>

[0117] As the antibody, four non-continuous batches (Lots. 1-4) of bevacizumab (Avastin: registered trademark, anti-VEGF humanized monoclonal antibody, manufactured by Chugai Pharmaceutical Co., Ltd.) were used, and the procedure was otherwise performed in the same manner as in Example 1. A graph showing the relationship between the detected glycan structure (glycan ID) and the relative amount is shown below. Figure 6 As shown in the figure, the relative amounts of glycan structures bonded to the antibody (especially the glycans ID33100, 43100, and 44100 shown in the figure) vary from batch to batch, indicating that the glycan structure is not uniform between batches.

[0118] <Examples 7-8: Comparison of Columns>

[0119] The column was modified as follows, except that the assay of the present invention was performed in the same manner as in Example 1 (Avastin, antibody amount equivalent to 500 fmol). The elution completion time and peak separation of SFC were observed at this time.

[0120] Example 7: Trade name "CHIRALPAK IF-3", containing 3-chloro-4-methylphenyl carbamate, particle size 3 μm, manufactured by Daicel Corporation.

[0121] Example 8: Trade name "Cellulose-C", cellulose tris(3,5-dimethylphenylcarbamate), particle size 3 μm, manufactured by YMC Corporation.

[0122] Comparing these results, the elution time for Example 7 was 2.32 minutes, and for Example 8 it was 2.75 minutes. Both examples had faster elution times compared to Example 1. However, the glycan peak separation was less complete in both examples compared to Example 1. Therefore, based on both elution speed and peak separation, the column of Example 1 is superior.

[0123] <Examples 9-10: Comparison of Replenished Solvents>

[0124] The analytical method of the present invention was carried out in largely the same manner as in Example 1, except that a quadrupole time-of-flight (QTOF) mass spectrometry (LCMS-9030, manufactured by Shimadzu Corporation) was used instead of a triple quadrupole mass spectrometer, with 2 pmol of ramucirumab as the antibody and the supplementary solvent set as described below.

[0125] The supplemental solvent was set to methanol containing 20 mM ammonium formate (Example 9) or methanol containing 0.1% (v / v) formic acid (Example 9), and analysis was performed. The results showed that, at the peak position with a retention time of 3.53 minutes, the peak intensity of Example 9 was 2.25 million counts (height), while the peak intensity of Example 10 was 1.13 million counts (height). This demonstrates that Example 9 exhibits excellent sensitivity.

[0126] Explanation of reference numerals in the attached figures

[0127] 1. Supercritical fluid chromatography apparatus 2. Mobile phase container 3. Pump 4. Sample introduction unit 5. Column 6. Detection unit 7. Computer 8. Modifier container 9. Replenishment solvent container 10. Pump 11. Pump 12. Sample 20. Tandem mass spectrometry apparatus 21. Ionization unit 22. First mass spectrometer 23. Fragment generation unit 24. Second mass spectrometer 25. Detection unit 26. Computer

Claims

1. A method for analyzing the structure of glycans bonded to antibodies, comprising: In the cleavage process, a sugar-cleaving enzyme is added to the antibody-containing sample to specifically cleave the sugar chains bonded to the antibody, thereby obtaining free sugar chains. The recycling process involves recovering the free sugar chains through affinity purification. The hydrophobication process involves hydrophobizing the free sugar chains to obtain hydrophobic sugar chains; and, The determination process involves sequentially performing supercritical fluid chromatography and tandem mass spectrometry analysis on the hydrophobic sugar chains.

2. The analytical method according to claim 1, wherein, The determination process includes an analysis process, which analyzes the structure of the glycans bonded to the antibody based on mass spectrometry analysis data obtained by supercritical fluid chromatography and tandem mass spectrometry.

3. The analytical method according to claim 1, wherein, The stationary phase used in the supercritical fluid chromatography contains phenyl groups.

4. The analytical method according to claim 1, wherein, In the hydrophobication process, the hydroxyl groups of the free sugar chain are modified with a hydrophobic compound.

5. The analytical method according to claim 1, wherein, The hydrophobication is acetylation.

6. The analytical method according to claim 1, wherein, In the determination process, an organic solvent containing a carboxylic acid or its salt is added to the free sugar chains after passing through the stationary phase of the supercritical fluid chromatography, followed by the tandem mass spectrometry analysis.

7. The analytical method according to claim 1, wherein, A triple quadrupole mass spectrometer was used in the tandem mass spectrometry analysis.

Citation Information

Patent Citations

  • Method, kit and device for preparing sugar chain of glycoprotein

    CN108138207A

  • Binding molecule for DBP and method for measuring vitamin d

    WO2012104643A1